关于各种酚噻嗪类药物并发的粒细胞缺乏症已有许多报导。一般认为用药的剂量与期限是发生本症的主要原因。此外,个体的易感性也是一重要因素。本症的发病率约为万分之一,一般在用药的头三个月内、且常在头十天内出现,但亦有在长期用药时发生者。为了防止其再发,可以换用其他同类的药物(常用哌嗪类衍生物),或者改用另一类的安定剂(如丁酰苯类或硫杂蒽类),如此往往有效。但有些病例无论换用何种安定剂,仍然会产生此并发症。作者报导三个病例,以说明粒细胞缺乏症发生的寻常与不寻常的过程。第一例说明粒细胞缺乏症的普通过程。病人在使用酚噻嗪类(Methotri-meprazine)后两个月末出现此并发症,白细胞降至2135/立方毫米,而中性白细胞只占3%。在停药后一周内血相恢复正常水平。作者认为此类型粒细 There have been many reports of agranulocytosis complicated with various phenothiazines. Generally believed that the dose and duration of medication is the main cause of this disease. In addition, individual susceptibility is also an important factor. The incidence of this disease is about one ten thousandths, usually within the first three months of medication, and often appear within the first ten days, but there are also those who occur in the long-term medication. In order to prevent its recurrence, it is often effective to switch to other similar drugs (commonly used piperazine derivatives) or to another type of stabilizer (such as butyrophenones or thioxantanes). However, in some cases, no matter what stabilizer to switch to, will still produce this complication. The authors report three cases to illustrate the unusual and unusual process of agranulocytosis. The first case illustrates the general process of agranulocytosis. The patient developed this complication at the end of two months after using methotri-meprazine, with leukopenia to 2135 per cubic millimeter, whereas neutrophils accounted for only 3%. Within a week after withdrawal from the blood normal level. The author thinks this type is fine